Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $350.2 million.

  • Avidity Biosciences' Cash & Equivalents fell 539.92% to $350.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $350.2 million, marking a year-over-year decrease of 539.92%. This contributed to the annual value of $219.9 million for FY2024, which is 1879.49% up from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Cash & Equivalents is $350.2 million, which was down 539.92% from $243.9 million recorded in Q2 2025.
  • Avidity Biosciences' Cash & Equivalents' 5-year high stood at $575.8 million during Q2 2024, with a 5-year trough of $85.6 million in Q3 2023.
  • In the last 5 years, Avidity Biosciences' Cash & Equivalents had a median value of $254.2 million in 2025 and averaged $267.7 million.
  • As far as peak fluctuations go, Avidity Biosciences' Cash & Equivalents plummeted by 6495.26% in 2022, and later surged by 33220.9% in 2024.
  • Avidity Biosciences' Cash & Equivalents (Quarter) stood at $320.4 million in 2021, then grew by 6.23% to $340.4 million in 2022, then plummeted by 45.63% to $185.1 million in 2023, then grew by 18.79% to $219.9 million in 2024, then soared by 59.28% to $350.2 million in 2025.
  • Its Cash & Equivalents stands at $350.2 million for Q3 2025, versus $243.9 million for Q2 2025 and $254.2 million for Q1 2025.